Patent number: 8415455
Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.
Type:
Grant
Filed:
September 3, 2008
Date of Patent:
April 9, 2013
Assignee:
Compugen Ltd
Inventors:
Zurit Levine, Tania Pergam, Dalit Landesman-Milo, Anat Cohen-Dayag, Amir Toporik, Yaron Kinar, Sergey Nemzer, Avi Rosenberg, Galit Rotman, Amit Novik, Cynthia Koifman, Merav Beiman, Liat Dassa, Shira Walach, Eve Montia, Shirley Sameach-Greenwald, Ofer Levy, Marina Bubis
Publication number: 20120134997
Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.
Type:
Application
Filed:
September 3, 2008
Publication date:
May 31, 2012
Applicant:
COMPUGEN LTD.
Inventors:
Zurit Levine, Tania Pergam, Dalit Milo, Anat Cohen-Dayag, Amir Toporik, Yaron Kinar, Sergey Nemzer, Avi Rosenberg, Galit Rotman, Amit Novik, Cynthia Koifman, Merav Beiman, Liat Dassa, Shira Walach, Eve Montia, Shirley Sameach-Greenwald, Oler Levy, Marina Bubis
Publication number: 20110091454
Abstract: Polypeptide sequences and polynucleotide sequences are provided. Also provided are annotative information concerning such sequences and uses for these sequences.
Type:
Application
Filed:
February 8, 2010
Publication date:
April 21, 2011
Inventors:
Alex Diber, Sarah Pollock, Zurit Levine, Sergey Nemzer, Vladimir Grebinskiy, Brian Meloon, Andrew Olson, Avi Rosenberg, Ami Haviv, Shaul Zevin, Tomer Zekharia, Zipi Shaked, Moshe Olshansky, Ariel Farkash, Eyal Privman, Amit Novik, Naomi Keren, Gad S. Cojocaru, Pinchas Akiva, Yossi Cohen, Ronen Shemesh, Osnat Sella-Tavor, Liat Mintz, Hanqing Xie, Dvir Dahary, Erez Levanon, Shiri Freilich, Nili Beck, Wei-Yong Zhu, Alon Wasserman, Chen Chermesh, Idit Azar, Rotem Sorek, Jeanne Bernstein